Lakefront Biotherapeutics NV current report, Q1 FY2026

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of March 2026. The filing serves to incorporate by reference a press release dated March 6, 2026, which is attached as Exhibit 99.1. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.

Financial Metrics

The provided filing text contains no financial data. It does not report revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a procedural filing to distribute a press release rather than a financial statement.

Material Changes

No material financial changes or comparative period data are disclosed in the text of this Form 6-K. The filing solely references the issuance of a press release on March 6, 2026.

Guidance, Outlook, and Risks

The filing text does not contain specific guidance, management commentary, risk factors, or details on contingencies. These items, if present, would be located within the attached Exhibit 99.1 (Press Release), the content of which is not included in the provided input.

Key Facts for Investor Verification

  • Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
  • Content Source: The substantive information is contained in Exhibit 99.1 (Press Release dated March 6, 2026), which is not included in the provided text.
  • Financial Data: No financial metrics are available in this specific document; investors must consult the press release or recent 20-F filings for financial status.
  • Filing Purpose: This document is a regulatory mechanism to incorporate the press release into the company's Registration Statements on Form S-8.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.